Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cindy Spittle
Observed names:
C Spittle,
C. S. Spittle,
C. Spittle
Observed institutions:
University of Southern California,
Fox Chase Cancer Center,
Lehigh University,
Information Management Services,
Division of Cancer Epidemiology and Genetics
ORCID:
0000-0001-6761-4822
Observed ORCID:
0000-0001-6761-4822
OpenAlex ID:
A5041152213
Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression
2015
·
Gregory A. Chang
, Jyothirmayee S. Tadepalli
, et al.
·
Molecular Oncology
·
72
PDF
Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium
2007
·
W.-C. L. Chang
, R. A. Coudry
, et al.
·
Carcinogenesis
·
65
Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression
2009
·
Xu-Zhi Xu
, Marileila Varella Garcia
, et al.
·
Modern Pathology
·
49
PDF
Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer Risk
2009
·
J. F. Dorgan
, F. Z. Stanczyk
, et al.
·
JNCI Journal of the National Cancer Institute
·
29
PDF
TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors
2020
·
Gregory A. Chang
, Jennifer M. Wiggins
, et al.
·
Journal of Investigative Dermatology
·
23
PDF
Immune-surveillance and programmed cell death-related genes are significantly overexpressed in the normal breast epithelium of postmenopausal parous women
2007
·
G. Balogh
, I. Russo
, et al.
·
International Journal of Oncology
·
13
PDF
Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma
2019
·
Mahrukh M. Syeda
, Jennifer M. Wiggins
, et al.
·
Methods in molecular biology
·
12
Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Cancer Tissue
2017
·
Jessica Kristof
, Kellen Sakrison
, et al.
·
Biomarker Insights
·
4
Abstract 1397: Oncomine focus assay: Simultaneous detection of clinically relevant hotspot mutations, CNVs, and gene fusions in 52 oncogenes relevant to solid tumors
2016
·
Peng Fang
, Zhenyu Yan
, et al.
·
Cancer Research
·
3
Detection of a novel RET gene fusion in a non-small cell lung cancer patient using AMP chemistry
2016
·
Peng Fang
, Zhenyu Yan
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
Abstract A66: Analytical validation of 7 droplet digital PCR assays detecting TERT, BRAF, and NRAS hotspot mutations in plasma-derived circulating tumor DNA (ctDNA)
2020
·
Mahrukh M. Syeda
, Broderick Corless
, et al.
·
Clinical Cancer Research
·
2
Abstract 4261: Oncomine® Cancer Panel: simultaneous detection of clinically relevant hotspot mutations, CNVs, and gene fusions in solid tumors
2015
·
Peng Fang
, Zhenyu Yan
, et al.
·
Cancer Research
·
2
Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance.
2012
·
Jin Li
, Weihua Liu
, et al.
·
Blood
·
2
Abstract 4522: An optimized NGS workflow for detection of FLT3 internal tandem duplication (ITD) in AML samples
2018
·
Xiaodong Wang
, Zhenyu Yan
, et al.
·
Cancer Research
·
1
Abstract 4925: Liquid biopsy using the ion AmpliSeq v2 cancer panel
2015
·
WeiHua Liu
, Zhenyu Yan
, et al.
·
Cancer Research
·
1
Abstract 896: Enhanced sensitivity detection of replication competent lentivirus by qPCR
2020
·
David Burke
, Kristine Drafahl
, et al.
·
Cancer Research
Abstract 4704: Identification of melanoma mutational tumor heterogeneity using BRAF, NRAS and TERT-promoter mutation-detection assays
2019
·
Gregory Chang
, Broderick Corless
, et al.
·
Cancer Research
Abstract 4704: Identification of melanoma mutational tumor heterogeneity using BRAF, NRAS and TERT-promoter mutation-detection assays
2019
·
Gregory Chang
, Broderick Corless
, et al.
·
Tumor Biology
Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
2018
·
Kristy Drafahl
, David C Smith
, et al.
·
Blood
Abstract 5531: Detection of co-occurring and potential resistance mutations in cell-free, circulating tumor DNA from patients with BRAF mutant metastatic melanoma undergoing treatment with BRAF-targeted therapies
2018
·
Broderick Corless
, Greg Chang
, et al.
·
Cancer Research
Abstract A044: Immunotherapy biomarker assessment in RCC using IHC, gene expression profiling, and mutation burden assessment
2018
·
Peng Fang
, Zhenyu Yan
, et al.
·
Molecular Cancer Therapeutics
Abstract B072: Liquid biopsy analysis of NSCLC patient plasma using ddPCR and NGS
2018
·
WeiHua Liu
, Peng Fang
, et al.
·
Molecular Cancer Therapeutics
Abstract A29: Mutation profiling of colorectal cancer ctDNA using AmpliSeq CHP2 cancer panel
2015
·
WeiHua Liu
, Zhenyu Yan
, et al.
·
Molecular Cancer Therapeutics
Abstract 2847: Quantitative assessment of circulating BRAF DNA in stage IV melanoma patients undergoing BRAF inhibitor treatment
2014
·
David Polsky
, Jyothi Sakuntala Tadepalli
, et al.
·
Cancer Research
Phasing Analysis Of TKI Resistance Mutations In The BCR-ABL1 Kinase Domain and Neighboring Domains Using Next-Generation Sequencing
2013
·
Jin Li
, Zhenyu Yan
, et al.
·
Blood
Show more works
View as search
Works count:
29
Citation count:
281
H-index:
7
I10-index:
7
Year
Topic
Type
